https://www.biopharmawatch.com/news/HCWB/hcw-biologics-private-placement-pricing BiopharmaWatch en 2026-09-24T12:25:00.000Z HCW Biologics Announces Pricing of $1.5 Million Private Placement https://www.biopharmawatch.com/news/ICU/seastar-medical-dr-humes-award-2026 BiopharmaWatch en 2026-09-24T12:16:00.000Z SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-imnn-001-study-update BiopharmaWatch en 2026-09-24T12:05:00.000Z IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan https://www.biopharmawatch.com/news/LABT/lakewood-amedeox-phase-2a-trial-nu-3-diabetic-foot-ulcers BiopharmaWatch en 2026-09-24T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers https://www.biopharmawatch.com/news/RVTY/revvity-launches-ivdr-solution-early-detection-type-1-diabetes BiopharmaWatch en 2026-09-24T12:00:00.000Z Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes https://www.biopharmawatch.com/news/CLGN/lightsolver-photonic-computing-accelerate-hpc BiopharmaWatch en 2026-09-24T12:00:00.000Z LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads https://www.biopharmawatch.com/news/ATOS/atossa-ceo-dr-quay-ardd-2026-panel BiopharmaWatch en 2026-09-24T12:00:00.000Z Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging https://www.biopharmawatch.com/news/ANNX/annexon-vonaprument-phase-3-archer-ii-trial BiopharmaWatch en 2026-09-24T12:00:00.000Z Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting https://www.biopharmawatch.com/news/NVCT/nuvectis-nxp200-breakthrough-therapy-designation-china BiopharmaWatch en 2026-09-24T12:00:00.000Z Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma https://www.biopharmawatch.com/news/LSTA/marea-therapeutics-mar001-presentation-aha-2026 BiopharmaWatch en 2026-09-24T12:00:00.000Z Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-amplify-7p-esmo-congress-2026 BiopharmaWatch en 2026-09-24T12:00:00.000Z Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-revera-301-phase-3-trial BiopharmaWatch en 2026-09-24T12:00:00.000Z Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR https://www.biopharmawatch.com/news/CRON/cronos-hosts-2026-investor-day BiopharmaWatch en 2026-09-24T12:00:00.000Z Cronos Hosts 2026 Investor Day https://www.biopharmawatch.com/news/SLBT/sl-science-preclinical-data-glioblastoma-therapy BiopharmaWatch en 2026-09-24T12:00:00.000Z SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-phase-2-protocol-cy200-crps BiopharmaWatch en 2026-09-24T12:00:00.000Z Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA https://www.biopharmawatch.com/news/ZTS/zoetis-webcast-conference-call-q3-2026-results BiopharmaWatch en 2026-09-24T11:30:00.000Z Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PFSA/profusa-lumee-oxygen-platform-ce-mark-progress BiopharmaWatch en 2026-09-24T11:30:00.000Z Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October https://www.biopharmawatch.com/news/KALA/kala-bio-virotek-dna-testing-partnership BiopharmaWatch en 2026-09-24T11:30:00.000Z Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products https://www.biopharmawatch.com/news/IMRX/immuneering-esmo-congress-2026-presentation BiopharmaWatch en 2026-09-24T11:30:00.000Z Immuneering to Present at the ESMO Congress 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-500-million-offering BiopharmaWatch en 2026-09-24T11:05:00.000Z Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes https://www.biopharmawatch.com/news/ACAD/acadia-phase-3-results-remlifanserin-alzheimers-psychosis BiopharmaWatch en 2026-09-24T11:00:00.000Z Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) https://www.biopharmawatch.com/news/MESO/mesoblast-fda-approval-new-potency-assay-ryoncil BiopharmaWatch en 2026-09-24T11:00:00.000Z Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-q4-2026-milestones BiopharmaWatch en 2026-09-24T11:00:00.000Z Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio https://www.biopharmawatch.com/news/MSLE/satellos-fda-clearance-forazapadin-fshd-partnership BiopharmaWatch en 2026-09-24T11:00:00.000Z Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development https://www.biopharmawatch.com/news/MRK/merck-remigromig-brunello-trial-results BiopharmaWatch en 2026-09-24T10:45:00.000Z Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema https://www.biopharmawatch.com/news/BDSX/biodesix-mrd-monitoring-advancements BiopharmaWatch en 2026-09-24T10:00:00.000Z Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring https://www.biopharmawatch.com/news/ATYR/atyr-pharma-fda-phase-3-study-efzofitimod BiopharmaWatch en 2026-09-24T10:00:00.000Z aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis https://www.biopharmawatch.com/news/MNOV/medicinova-completes-last-patient-visit-combat-als-trial BiopharmaWatch en 2026-09-24T10:00:00.000Z MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-miv-cel-positive-data-sps-gmg BiopharmaWatch en 2026-09-24T10:00:00.000Z Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis https://www.biopharmawatch.com/news/IDXX/idexx-fecal-dx-antigentest-taeniid-tapeworms BiopharmaWatch en 2026-09-24T07:00:00.000Z IDEXX erweitert den Fecal Dx Antigentest um den Nachweis von Taeniid-Bandwürmern https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-report-2026-financial-results BiopharmaWatch en 2026-09-24T05:00:00.000Z Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 https://www.biopharmawatch.com/news/GRML/greenland-mines-completes-equity-financing-through-2027 BiopharmaWatch en 2026-09-24T04:21:00.000Z Greenland Mines Completes $12-Per-Share Equity Financing, Fully Funded Through 2027 Milestones with $42 Million, Terminates ATM, and Completes Sarfartoq Rare Earth Field Program https://www.biopharmawatch.com/news/ACB/aurora-cannabis-curaleaf-bid-disclosure-issues BiopharmaWatch en 2026-09-23T22:28:00.000Z Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure https://www.biopharmawatch.com/news/GRAL/fda-committee-approves-grail-galleri-test BiopharmaWatch en 2026-09-23T22:17:00.000Z FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-cloud-analysis-tool-launch BiopharmaWatch en 2026-09-23T21:00:00.000Z Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool https://www.biopharmawatch.com/news/ATEC/atec-appoints-tommy-carls-executive-vice-president BiopharmaWatch en 2026-09-23T20:35:00.000Z ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-offers-common-stock-notes BiopharmaWatch en 2026-09-23T20:32:00.000Z Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes https://www.biopharmawatch.com/news/POCI/precision-optics-fiscal-2026-conference-call BiopharmaWatch en 2026-09-23T20:15:00.000Z Precision Optics Schedules Fourth Quarter and Fiscal Year 2026 Conference Call for September 28, 2026 https://www.biopharmawatch.com/news/EVMN/evommune-phase-2a-evo301-atopic-dermatitis-presentation BiopharmaWatch en 2026-09-23T20:05:00.000Z Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress https://www.biopharmawatch.com/news/MLYS/mineralys-transform-htn-trial-data-presentation-aha-2026 BiopharmaWatch en 2026-09-23T20:05:00.000Z Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/SRXH/srx-global-webinar-fintech-investment BiopharmaWatch en 2026-09-23T20:05:00.000Z SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-otc-deficiency-phase-2-results BiopharmaWatch en 2026-09-23T20:01:00.000Z Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-appoints-bo-cumbo-board-directors BiopharmaWatch en 2026-09-23T20:01:00.000Z Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization https://www.biopharmawatch.com/news/GOSS/gossamer-bio-submits-nda-seralutinib-pah BiopharmaWatch en 2026-09-23T20:01:00.000Z Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension https://www.biopharmawatch.com/news/IMCC/im-cannabis-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-23T20:01:00.000Z IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/MDXG/mimedx-federal-court-ruling-axiofill-classification BiopharmaWatch en 2026-09-23T20:01:00.000Z MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter https://www.biopharmawatch.com/news/ZYME/zymeworks-acquisition-theravance-biopharma BiopharmaWatch en 2026-09-23T20:01:00.000Z Zymeworks Completes Acquisition of Theravance Biopharma https://www.biopharmawatch.com/news/NAMS/menarini-newamsterdam-european-approval-ubeslo-evlarco BiopharmaWatch en 2026-09-23T17:43:00.000Z Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco® https://www.biopharmawatch.com/news/ARMP/clinical-supply-manager-armata-pharmaceuticals BiopharmaWatch en 2026-09-23T16:55:32.000Z Clinical Supply Manager https://www.biopharmawatch.com/news/ARMP/clinical-research-associate-cra-armata-pharmaceuticals BiopharmaWatch en 2026-09-23T16:50:28.000Z Clinical Research Associate (CRA) https://www.biopharmawatch.com/news/CVS/cv-health-reminds-tennessee-vaccines-available BiopharmaWatch en 2026-09-23T16:09:00.000Z As measles cases rise in Tennessee, CVS Health® reminds residents that vaccines are available statewide https://www.biopharmawatch.com/news/SNN/smith-nephew-evos-pelvic-plating-system-launch BiopharmaWatch en 2026-09-23T15:11:00.000Z Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management https://www.biopharmawatch.com/news/BMY/bms-joins-raap-rare-access-action-project BiopharmaWatch en 2026-09-23T14:01:00.000Z New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP https://www.biopharmawatch.com/news/CHRS/coherus-oncology-markets-biosimilar-assets BiopharmaWatch en 2026-09-23T13:30:00.000Z Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets https://www.biopharmawatch.com/news/NXGL/nexgel-announces-investor-update-call-details BiopharmaWatch en 2026-09-23T13:29:00.000Z NEXGEL Announces Dial-In Details for Investor Update Call https://www.biopharmawatch.com/news/TECH/bio-techne-merck-acquisition-approval BiopharmaWatch en 2026-09-23T13:20:00.000Z Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany https://www.biopharmawatch.com/news/HCTI/hcti-acquires-roboticom-industrial-automation BiopharmaWatch en 2026-09-23T13:17:00.000Z Healthcare Triangle Signs Letter of Intent to Pursue the Proposed Acquisition of Roboticom's Cutting-Edge Industrial Precision Robotics Automation Business https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-thio-104-trial-expansion-spain-portugal BiopharmaWatch en 2026-09-23T13:17:00.000Z MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal https://www.biopharmawatch.com/news/BCDA/biocardia-fda-helix-pre-submission-update BiopharmaWatch en 2026-09-23T13:15:00.000Z BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-stifel-2026-forum BiopharmaWatch en 2026-09-23T13:00:00.000Z Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum https://www.biopharmawatch.com/news/AGL/agilon-health-springfield-clinic-partnership-expansion BiopharmaWatch en 2026-09-23T13:00:00.000Z agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO https://www.biopharmawatch.com/news/LIVN/livanova-third-quarter-2026-results-announcement BiopharmaWatch en 2026-09-23T13:00:00.000Z LivaNova to Announce Third-Quarter 2026 Results https://www.biopharmawatch.com/news/GCTK/lokahi-therapeutics-strategic-update-lt-100-ai2-platform BiopharmaWatch en 2026-09-23T13:00:00.000Z Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities https://www.biopharmawatch.com/news/MRK/merck-manuals-inform-patients-inflammatory-bowel-disease BiopharmaWatch en 2026-09-23T13:00:00.000Z Merck Manuals Details What Patients Need to Know About Inflammatory Bowel Disease https://www.biopharmawatch.com/news/EHTH/ehealth-partners-bernieportal-choice-arrangements BiopharmaWatch en 2026-09-23T13:00:00.000Z eHealth Partners with BerniePortal to Provide Integrated CHOICE Arrangements for Employers and Brokers https://www.biopharmawatch.com/news/OPTH/optimi-health-psilocybin-production-phase-2-trial BiopharmaWatch en 2026-09-23T13:00:00.000Z Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply https://www.biopharmawatch.com/news/IRMD/iradimed-participate-roth-healthcare-conference BiopharmaWatch en 2026-09-23T13:00:00.000Z IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference https://www.biopharmawatch.com/news/BNGO/bionano-expands-ogm-testing-hematologic-cancers BiopharmaWatch en 2026-09-23T13:00:00.000Z Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies https://www.biopharmawatch.com/news/LINC/lincoln-educational-services-lawsuit BiopharmaWatch en 2026-09-23T12:55:00.000Z Shareholders who lost money in shares of acquired Lincoln Educational Services Corporation (NASDAQ: LINC) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/PALI/palisade-bio-expands-phase-2b-ascentra-uc-program BiopharmaWatch en 2026-09-23T12:45:00.000Z Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance https://www.biopharmawatch.com/news/IMCC/im-cannabis-announces-1-31-million-offering BiopharmaWatch en 2026-09-23T12:37:00.000Z IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-patent-portfolio-expansion BiopharmaWatch en 2026-09-23T12:35:00.000Z SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations https://www.biopharmawatch.com/news/VBIO/valion-appoints-dean-zikria-interim-ceo-leadership-transitions BiopharmaWatch en 2026-09-23T12:33:10.321Z Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions https://www.biopharmawatch.com/news/GRML/greenland-mines-doubles-mining-footprint-west-greenland BiopharmaWatch en 2026-09-23T12:30:00.000Z Greenland Mines Ltd. (NASDAQ: GRML) Applies to More than Double Mining Footprint in West Greenland https://www.biopharmawatch.com/news/TMO/thermo-fisher-gibco-cho-k1-catalog-panel-launch BiopharmaWatch en 2026-09-23T12:30:00.000Z Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development https://www.biopharmawatch.com/news/MBRX/moleculin-biotech-mexican-patent-annamycin BiopharmaWatch en 2026-09-23T12:25:00.000Z Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 https://www.biopharmawatch.com/news/AZN/polaris-rx-exclusive-distributor-astrazeneca-flumist-home BiopharmaWatch en 2026-09-23T12:10:00.000Z Polaris Rx Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service for Second Consecutive Year https://www.biopharmawatch.com/news/MXCT/maxcyte-appoints-sidharth-kapileshwar-corporate-development-officer BiopharmaWatch en 2026-09-23T12:05:00.000Z MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer https://www.biopharmawatch.com/news/TPST/tempest-appoints-nancy-freda-smith-board BiopharmaWatch en 2026-09-23T12:00:20.000Z Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors https://www.biopharmawatch.com/news/MGTX/meiragtx-appoints-alan-sebulsky-board-directors BiopharmaWatch en 2026-09-23T12:00:15.000Z MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors https://www.biopharmawatch.com/news/ADGM/adagio-medical-strategic-review-shareholder-value BiopharmaWatch en 2026-09-23T12:00:00.000Z Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presentation-discovery-target-conference BiopharmaWatch en 2026-09-23T12:00:00.000Z Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA https://www.biopharmawatch.com/news/CORT/corcept-leadership-transition BiopharmaWatch en 2026-09-23T12:00:00.000Z Corcept Announces Planned Leadership Transition https://www.biopharmawatch.com/news/MCK/mckesson-fiscal-2027-earnings-release-date BiopharmaWatch en 2026-09-23T12:00:00.000Z McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date https://www.biopharmawatch.com/news/LXEO/apertura-gene-therapy-lexeo-therapeutics-friedreich-ataxia BiopharmaWatch en 2026-09-23T12:00:00.000Z Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia https://www.biopharmawatch.com/news/PRQR/proqr-appoints-ai-officers-strategic-advisor BiopharmaWatch en 2026-09-23T12:00:00.000Z ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor https://www.biopharmawatch.com/news/ANVS/annovis-partnership-weave-bio-nda-buntanetap-alzheimers BiopharmaWatch en 2026-09-23T12:00:00.000Z Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease https://www.biopharmawatch.com/news/ALT/altimmune-participate-stifel-cardiometabolic-forum BiopharmaWatch en 2026-09-23T12:00:00.000Z Altimmune to Participate in Stifel Cardiometabolic Forum https://www.biopharmawatch.com/news/LTRN/lantern-pharma-agentic-ai-drug-development-presentation BiopharmaWatch en 2026-09-23T11:45:00.000Z Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET https://www.biopharmawatch.com/news/DCGO/docgo-webinar-hicuity-health-acquisition-details BiopharmaWatch en 2026-09-23T11:35:00.000Z DocGo Announces Upcoming Webinar to Outline Vision and Details of the Pending Hicuity Health Acquisition https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art27-13-obesity-patent-filing BiopharmaWatch en 2026-09-23T11:33:00.000Z Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings https://www.biopharmawatch.com/news/IMCC/im-cannabis-acquires-space-defense-innovations BiopharmaWatch en 2026-09-23T11:30:00.000Z IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-allonk-clinical-data-symposium BiopharmaWatch en 2026-09-23T11:30:00.000Z Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease https://www.biopharmawatch.com/news/WVE/wave-life-sciences-phase-2a-trial-wve-007-tirzepatide-obesity BiopharmaWatch en 2026-09-23T11:30:00.000Z Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity https://www.biopharmawatch.com/news/BMEA/biomea-fusion-terminates-public-offering-securities BiopharmaWatch en 2026-09-23T11:03:00.000Z Biomea Fusion Announces Termination of Proposed Public Offering of Securities https://www.biopharmawatch.com/news/PBM/psyence-biomeds-strategic-ibogaine-investment BiopharmaWatch en 2026-09-23T11:00:19.000Z Psyence BioMed Announces Strategic Ibogaine Investment https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-clinical-update-life-sciences-future-2026 BiopharmaWatch en 2026-09-23T11:00:00.000Z Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-patent-allowance-fsparin-fsgs BiopharmaWatch en 2026-09-23T11:00:00.000Z Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis https://www.biopharmawatch.com/news/GKOS/glaukos-launches-could-it-be-kc-campaign BiopharmaWatch en 2026-09-23T11:00:00.000Z Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-additional-funding-phase-3-development BiopharmaWatch en 2026-09-23T11:00:00.000Z Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development https://www.biopharmawatch.com/news/CTSO/cytosorbents-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-23T11:00:00.000Z CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/ROIV/roivant-proof-of-concept-imvt-1402-lupus-results BiopharmaWatch en 2026-09-23T11:00:00.000Z Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus https://www.biopharmawatch.com/news/ACIU/ac-immune-positive-results-vacsyn-phase-2-trial BiopharmaWatch en 2026-09-23T11:00:00.000Z AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 https://www.biopharmawatch.com/news/IMVT/immunovant-imvt-1402-cutanous-lupus-results BiopharmaWatch en 2026-09-23T11:00:00.000Z Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-positive-week-28-data-orka-001 BiopharmaWatch en 2026-09-23T11:00:00.000Z Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-23T11:00:00.000Z Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-eadv-congress-2026 BiopharmaWatch en 2026-09-23T11:00:00.000Z Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-fda-approval-everolimus-tablets BiopharmaWatch en 2026-09-23T10:55:00.000Z ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-phase-iii-maveric-enrollment-expansion BiopharmaWatch en 2026-09-23T10:00:00.000Z Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy https://www.biopharmawatch.com/news/VICP/retransmission-vicapsys-life-sciences-completes-reverse-merger-stateline-distributors BiopharmaWatch en 2026-09-23T08:30:00.000Z RETRANSMISSION: Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets https://www.biopharmawatch.com/news/NNVC/phase-ii-trial-nv-387-monkeypox-drc BiopharmaWatch en 2026-09-23T08:30:00.000Z Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides https://www.biopharmawatch.com/news/VIVI/tempramed-distribution-agreement-centerwell-pharmacy BiopharmaWatch en 2026-09-23T07:05:00.000Z TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana https://www.biopharmawatch.com/news/MBX/microbix-presentation-muskoka-capital-event-2026 BiopharmaWatch en 2026-09-23T07:00:00.000Z Microbix Presenting at Muskoka Capital Event https://www.biopharmawatch.com/news/IONS/ionis-positive-interim-data-phase-3-imagination-study BiopharmaWatch en 2026-09-23T05:00:00.000Z Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) https://www.biopharmawatch.com/news/INNV/innovage-announces-pricing-secondary-offering-common-stock-selling-stockholders BiopharmaWatch en 2026-09-23T00:46:00.000Z InnovAge Announces Pricing of Secondary Offering of Common Stock by Selling Stockholders https://www.biopharmawatch.com/news/NUTX/nutex-health-dual-listing-nasdaq-texas BiopharmaWatch en 2026-09-22T22:50:00.000Z Nutex Health Approved for Dual Listing on Nasdaq Texas https://www.biopharmawatch.com/news/FWTC/firstline-venture-partners-acquires-forward-water-technologies BiopharmaWatch en 2026-09-22T22:16:00.000Z Early Warning Press Release - FirstLine Venture Partners Corporation Announces Acquisition of Securities of Forward Water Technologies Corp. https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-correction-warrant-inducement BiopharmaWatch en 2026-09-22T22:14:00.000Z Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release https://www.biopharmawatch.com/news/GEHC/ge-healthcare-dividend-increase-q3-2026 BiopharmaWatch en 2026-09-22T21:25:00.000Z GE HealthCare announces cash dividend increase for third quarter of 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-shareholder-meeting-results-name-change BiopharmaWatch en 2026-09-22T21:00:00.000Z Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change https://www.biopharmawatch.com/news/DGX/quest-diagnostics-third-quarter-results-october-2026 BiopharmaWatch en 2026-09-22T20:28:00.000Z Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 https://www.biopharmawatch.com/news/INCY/incyte-eadv-2026-inflammation-autoimmunity-data BiopharmaWatch en 2026-09-22T20:23:00.000Z Riassunto: I dati di Incyte al Congresso dell'Accademia Europea di Dermatologia e Venereologia (EADV) sottolineano l'ampiezza del portafoglio Infiammazione e Autoimmunità di Incyte https://www.biopharmawatch.com/news/INCY/incyte-eadv-2026-data-presentation BiopharmaWatch en 2026-09-22T20:22:00.000Z Samenvatting: De gegevens van Incyte op het congres van de Europese Academie voor Dermatologie en Venereologie (EADV) bevestigen de breedte van Incyte's portfolio op het gebied van ontsteking en auto-immuniteit https://www.biopharmawatch.com/news/TLSI/trisalus-fda-clearance-trinav-advance BiopharmaWatch en 2026-09-22T20:15:00.000Z TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization https://www.biopharmawatch.com/news/DHR/danaher-third-quarter-2026-earnings-call BiopharmaWatch en 2026-09-22T20:15:00.000Z Danaher Schedules Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/MEDP/medpace-holdings-third-quarter-2026-results BiopharmaWatch en 2026-09-22T20:05:00.000Z Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-appoints-pascal-desroches-board BiopharmaWatch en 2026-09-22T20:05:00.000Z GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors https://www.biopharmawatch.com/news/INNV/innovage-secondary-offering-common-stock BiopharmaWatch en 2026-09-22T20:02:00.000Z InnovAge Announces Launch of Proposed Secondary Offering of Common Stock by Selling Stockholders https://www.biopharmawatch.com/news/INAB/in8bio-sidoti-small-cap-conference-2026 BiopharmaWatch en 2026-09-22T20:00:00.000Z IN8bio to Present at Sidoti Small-Cap Virtual Conference https://www.biopharmawatch.com/news/NTHI/neonc-delivery-change-brain-cancer-equation BiopharmaWatch en 2026-09-22T18:52:00.000Z NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier https://www.biopharmawatch.com/news/ONNVF/onco-innovations-redwood-ai-terry-fox-grant-synograph BiopharmaWatch en 2026-09-22T18:00:00.000Z Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph(TM) Oncology Platform https://www.biopharmawatch.com/news/ONMD/atropos-health-expands-evidence-network BiopharmaWatch en 2026-09-22T17:40:00.000Z Atropos Health Scales Federated Evidence Network with Multimodal Data Partners to Accelerate Health Analytics and AI Model Development https://www.biopharmawatch.com/news/GRML/greenland-security-pact-reshapes-rare-earth-supply BiopharmaWatch en 2026-09-22T17:13:41.000Z Greenland Security Pact Reshapes the Race for Rare Earth Supply https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-warrant-inducement-transaction BiopharmaWatch en 2026-09-22T16:50:00.000Z Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results BiopharmaWatch en 2026-09-22T16:05:00.000Z Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results https://www.biopharmawatch.com/news/ENOV/enovis-sponsors-aaos-registry-program BiopharmaWatch en 2026-09-22T16:02:00.000Z Enovis becomes first multi-registry industry sponsor of AAOS Registry Program https://www.biopharmawatch.com/news/GRML/greenland-mines-applauds-formal-signing-u-s-denmark-greenland-security BiopharmaWatch en 2026-09-22T16:00:00.000Z Greenland Mines Applauds Formal Signing of U.S.-Denmark-Greenland Security Agreement at United Nations https://www.biopharmawatch.com/news/PFE/pfizer-webcast-november-3-conference-call BiopharmaWatch en 2026-09-22T14:00:00.000Z Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts https://www.biopharmawatch.com/news/TAK/takeda-esmo-2026-oncology-pipeline-progress BiopharmaWatch en 2026-09-22T13:30:00.000Z Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 https://www.biopharmawatch.com/news/RLAY/x-chem-phase-3-milestone-relay-therapeutics BiopharmaWatch en 2026-09-22T13:30:00.000Z X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-expands-parkinsons-platform-tanaist-agreement BiopharmaWatch en 2026-09-22T13:20:00.000Z Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement https://www.biopharmawatch.com/news/LGND/sydnexis-royalty-agreement-ligand-ryjunea BiopharmaWatch en 2026-09-22T13:02:00.000Z Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® https://www.biopharmawatch.com/news/TECH/bio-techne-customer-experience-center-duesseldorf BiopharmaWatch en 2026-09-22T13:00:00.000Z Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration https://www.biopharmawatch.com/news/AMGN/amgen-positive-topline-phase-3-results-dazodalibep-sjogrens BiopharmaWatch en 2026-09-22T13:00:00.000Z AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE https://www.biopharmawatch.com/news/OPTH/optimi-health-appoints-dr-michael-blough-cdo BiopharmaWatch en 2026-09-22T13:00:00.000Z Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-treatment BiopharmaWatch en 2026-09-22T12:55:18.000Z AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib https://www.biopharmawatch.com/news/RVMD/ampligen-role-pancreatic-cancer-treatment-fda-approval BiopharmaWatch en 2026-09-22T12:55:00.000Z AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-phase-3-trial-nsclc-progress BiopharmaWatch en 2026-09-22T12:47:00.000Z MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/ONMD/onemednet-expands-commercial-reach-atropus-health BiopharmaWatch en 2026-09-22T12:40:00.000Z OneMedNet Expands Commercial Reach Through Multi-Year Resale Agreement with Atropos Health https://www.biopharmawatch.com/news/PALI/palisade-bio-fda-clearance-ind-pali-2108-crohns-disease BiopharmaWatch en 2026-09-22T12:35:00.000Z Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD https://www.biopharmawatch.com/news/PLRZ/polyrizon-first-patient-nasarix-allergy-blocker BiopharmaWatch en 2026-09-22T12:33:00.000Z Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker https://www.biopharmawatch.com/news/SABS/sab-bio-present-sab-142-data-easd-2026 BiopharmaWatch en 2026-09-22T12:30:28.000Z SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes https://www.biopharmawatch.com/news/COCH/envoy-medical-new-patents-global-patent-portfolio BiopharmaWatch en 2026-09-22T12:30:00.000Z Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-world-narcolepsy-day-2026 BiopharmaWatch en 2026-09-22T12:30:00.000Z Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community https://www.biopharmawatch.com/news/GRML/ree-critical-metals-demand-western-nations-alternatives BiopharmaWatch en 2026-09-22T12:30:00.000Z REE, Critical Metals Demand Surging as Western Nations Race to Secure Alternatives https://www.biopharmawatch.com/news/INCY/incyte-eadv-congress-inflammation-autoimmunity-portfolio BiopharmaWatch en 2026-09-22T12:30:00.000Z Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio https://www.biopharmawatch.com/news/QTI/qt-imaging-honored-premier-supplier-innovation BiopharmaWatch en 2026-09-22T12:30:00.000Z QT Imaging to be Honored at Premier’s Annual Supplier Innovation Celebration https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-investor-event-casdatifan-kidney-cancer BiopharmaWatch en 2026-09-22T12:30:00.000Z Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-1-data-eortc-nci-aacr-symposium BiopharmaWatch en 2026-09-22T12:30:00.000Z Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/CMPX/compass-therapeutics-regulatory-update-tovecimig-btc BiopharmaWatch en 2026-09-22T12:30:00.000Z Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-fda-fast-track-qrx003-peeling-skin-syndrome BiopharmaWatch en 2026-09-22T12:30:00.000Z Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-cancer-data-eras-0015 BiopharmaWatch en 2026-09-22T12:30:00.000Z Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015